![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas (X.W., E.P., R.L., S.Y., J.W.S.); Migenix, Inc., San Diego, California (J.A.D.); and Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri (D.F.C.)
Received January 16, 2006; accepted April 13, 2006
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
-estradiol (17-E2) increases cell survival against H2O2 toxicity in human neuroblastoma cells. 17-E2 effectively reduced lipid peroxidation induced by 5-min H2O2 exposure. Furthermore, 17-E2 exerts the protective effects by maintaining intracellular Ca2+ homeostasis, attenuating ATP depletion, ablating mitochondrial calcium overloading, and preserving mitochondrial membrane potential. Two nonfeminizing estrogens, 17
- and ent-estradiol, were as effective as 17-E2 in increasing cell survival, alleviating lipid peroxidation, preserving mitochondrial function, and maintaining intracellular glutathione levels and Ca2+ homeostasis against H2O2 insult. Moreover, the estrogen receptor antagonist fulvestrant (ICI 182,780) did not block effects of 17-E2, but increased cell survival and blunted intracellular Ca2+ increases. However, these estrogens failed to reduce cytosolic reactive oxygen species, even at concentrations as high as 10 µM. In conclusion, estrogens exert protective effects against oxidative stress by inhibiting lipid peroxidation and subsequently preserving Ca2+ homeostasis, mitochondrial membrane potential, and ATP levels.
; Birge, 1996; Sherwin, 1996; Tang et al., 1996; Yaffe et al., 1998; Costa et al., 1999; Bagger et al., 2005). In addition, estrogen therapy is associated with decreased incidence and enhanced recovery from ischemic stroke. In in vitro studies, protective effects of estrogen have been widely reported in different types of neuronal cells against a variety of insults, including H2O2 (Behl et al., 1995, 1997; Sawada et al., 1998; Singer et al., 1998; Moosmann and Behl, 1999; Green et al., 2000), serum deprivation (Bishop and Simpkins, 1994; Green et al., 1997a,b; Bae et al., 2000), oxygen-glucose deprivation (Regan and Guo, 1997; Wilson et al., 2000), iron (Goodman et al., 1996; Blum-Degen et al., 1998), amyloid peptide-induced toxicity (Behl et al., 1995, 1997; Green et al., 1996; Gridley et al., 1997; Mattson et al., 1997; Pike, 1999), excitotoxicity (Goodman et al., 1996; Singer et al., 1996, 1999; Regan and Guo, 1997; Zaulyanov et al., 1999; Green and Simpkins, 2000), and mitochondrial toxins such as 3-nitropropionic acid (Wang et al., 2001a), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (De Girolamo et al., 2001), and sodium azide (Regan and Guo, 1997).
In in vivo studies, the neuroprotective effects of estrogens have been demonstrated in a variety of models of acute cerebral ischemia. These include transient and permanent middle cerebral artery occlusion models (Simpkins et al., 1997; Alkayed et al., 1998; Dubal et al., 1998), global forebrain ischemia models (Sudo et al., 1997), photothrombotic focal ischemia models (Fukuda et al., 2000), and glutamateinduced focal cerebral ischemia models (Mendelowitsch et al., 2001). The protective effects of estrogens have been described in rats, mice, and gerbils (Simpkins et al., 1997; Culmsee et al., 1999; Chen et al., 2001). Estrogen-induced neuroprotection has been demonstrated in adult female rats, middleaged female rats, and reproductively senescent female rats (Wise et al., 2001). Furthermore, nonfeminizing estrogens, including 17-estradiol (17-E2), a weak natural estrogen, and ent-E2, the enantiomer of 17-estradiol (17-E2), showed neuroprotective effects (Green et al., 2001; Liu et al., 2002; Perez et al., 2005). As shown in Fig. 1, 17-, 17-, and ent-E2 have phenolic A-ring, which is a key structure in neuroprotection by estrogen.
|
; Melov, 2000). As the major source of intracellular ATP and free radicals, mitochondria sit at a strategic position of life-death decision of a cell. H2O2 is a major reactive oxygen species (ROS) and a by-product of normal cellular function produced by superoxide dismutase and monoamine oxidase.
The aim of the present study was to investigate the protective effects of estrogens on mitochondrial function against a major ROS, H2O2. To illuminate the role of estrogen receptors in mitochondrial protection, we evaluated the effects of two nonfeminizing estrogens, 17-E2 and ent-E2, and assessed estrogen effects in the presence of an estrogen receptor (ER) antagonist, fulvestrant (ICI 182,780).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-E2 and 17-E2 were purchased from Steraloids (Newport, RI). ICI 182,780 was purchased from Tocris Cookson Inc. (Ellisville, MO). The enantiomer of 17-estradiol, ent-E2, was synthesized using methods that we have described previously (Green et al., 2001). H2O2 was purchased from Mallinckrodt Baker Inc. (Paris, KY). Calcein AM, 2,7-dichlorofluorescin diacetate (DCFH-DA), nonyl acridine orange (NAO), tetramethylrhodamine (TMR), Fura-2 AM, rhod-2 AM, and ATP determination kits were purchased from Molecular Probes (Eugene, OR). Trichloroacetic acid, 2-thiobarbituric acid (TBA), 1,1,3,3-tetramethoxypropane, and HCl were purchased from Sigma-Aldrich (St. Louis, MO).
All steroids and ICI 182,780 were dissolved in ethanol at a final concentration of 10 mM and diluted to appropriate concentration in culture media as required. Unless otherwise stated, steroid treatments of cell cultures involved a 2-h preincubation followed by coadministration of the steroid with H2O2. Hereafter, this treatment is referred to as pretreatment. Those cells receiving vehicle (in place of estradiol) pretreatment were maintained in fresh culture medium at the same final ethanol concentration. Control cells were maintained in culture medium with appropriate changes of fresh medium. In experiments involving the estrogen receptor antagonist, ICI 182,780 was added 30 min before addition of 17-E2.H2O2 was diluted with culture media to final concentration before use.
Cell Culturing. SK-N-SH human neuroblastoma cells were obtained from American Type Culture Collection (Manassas, VA) at passage 38 and were grown to confluence in RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT/Tissue Culture Biologicals, Tulare, CA), 20 µg/ml gentamicin (Sigma-Aldrich) in monolayers in plastic Nunc 75-cm2 flasks (Fisher Scientific Co., Orlando, FL) at 37°C and under 5% CO2, 95% air. Medium was changed three times weekly. Cells were observed with a phase-contrast microscope (Nikon Diaphot-300). SK-N-SH cells were back-cultured every 5 to 7 days using standard trypsinization procedures to maintain the cell line. SK-N-SH cells were used in passages 39 to 48.
Cell Viability Assay. Cell viability was determined using Calcein AM assay. SK-N-SH cells were plated at a density of 20,000 cells/well in 96-well plates 72 h before initiation of experiments. Cells were exposed to H2O2 (100 or 150 µM) for 18 h. Then, cells were rinsed with PBS, pH 7.4, and viability was assessed by calcein AM assay as described previously (Green et al., 2001). Percentage of viability was calculated by normalization of all values to the H2O2-free control group (=100%).
Intracellular Calcium Measurements. Cytosolic Ca2+ concentrations were measured using the ratiometric fluorescent indicator dye Fura-2 AM (Molecular Probes). SK-N-SH cells were plated on 25-mm coverslips in 35-mm dishes at the density of 6.0
7.0 x 105 cells/ml/dish 24 h before experimentation. Confluent SK-N-SH cell monolayers in the presence or absence of E2 pretreatment grown on coverslips were incubated at 37°C in RPMI 1640 medium containing 3 µM Fura-2 AM for 30 min. Then, coverslips were washed with HEPES-buffered salt solution (HBSS, containing 145 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose; pH adjusted to 7.4 with NaOH) three times to remove excess Fura-2 AM. Each coverslip then was inserted into the microincubator chamber of a MetaFluor system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Three milliliters of HBSS containing vehicle (0.01% ethanol, estrogens, or ICI 182,780) was added into the chamber. Treatment with H2O2 was carried out by adding the appropriate concentrations into the chamber. The excitation wavelength was alternated between 340 and 380 nm, and emission fluorescence was recorded at 510 nm. The fluorescence ratio was calculated as F340/F380. The system was calibrated using solutions containing either no Ca2+ or a saturating level of Ca2+. The equivalent in Ca2+ concentration was calculated using the formula [Ca2+]i = Kd [(R - Rmin)/ (Rmax - R)] (Fmin/Fmax). Data were analyzed using Prism 3.0 (Graph-Pad Software Inc., San Diego, CA).
Mitochondrial Calcium Measurement. Mitochondrial Ca2+ concentrations were measured using the mitochondrial-specific fluorescent indicator dye rhod-2 AM (Molecular Probes). SK-N-SH cells were plated on coverslips and cultured to reach 50% confluence. The cells were incubated with 1 mM rhod-2 AM for 45 min at 37°C and then washed five to six times with HBSS. The coverslips were placed into a 25-mm cell chamber (ALA Scientific Instruments Inc., Westbury, NY) followed by loading 3 ml of HBSS containing estrogens or vehicle. After stabilization for several minutes, H2O2 was added to reach a final concentration of 150 µM. The calcium variations were monitored by fluorescence confocal microscopy (Carl Zeiss GmbH, Jena, Germany) with excitation/emission of 568/590 nm. A time series of seven confocal images at 5-min intervals were recorded in each experiment. The time series were analyzed using the software system LSM 410 invert laser scan microscope. Fluorescence intensity was analyzed using CImaging software (Compix Inc., Imaging System, Cranberry Township, PA).
Measurement of ATP Levels. Experiments were initiated by plating SK-N-SH cells at a density of 1.0 x 106 cells/well in 12-well plates. Forty-eight hours later, cells were exposed to 150 µM H2O2 for 1 h in the presence or absence of estrogens (17-E2,17-E2, and ent-E2). Cellular ATP levels were quantified using a luciferin and luciferase-based assay (Garewal et al., 1986). Cells were rinsed with PBS and lysed with ATP-releasing buffer containing 100 mM potassium phosphate buffer at pH 7.8, 2 mM EDTA, 1 mM dithiothreitol, and 1% Triton X-100; 10 µl of the lysate was taken for protein determination. Another 10 µl of the lysate was added to a Nunc 96-well plate. ATP concentrations in lysates were quantified using an ATP determination kit (Molecular Probes) according to the manufacturer's instruction. The 96-well plates were read using a SpectraMax GeminiXS plate reader (Molecular Devices, Sunnyvale, CA). A standard curve was generated using solutions of known ATP concentrations. ATP levels were calculated as nanomolar ATP per milligram of protein and normalized to levels in untreated control cultures.
Monitoring Mitochondrial Membrane Potential. For 
m determination, 24 h before assay, cells were plated in clear-bottom, black-walled, 96-well plates (Costar 3606; Corning Glassworks, Corning, NY). Cells were plated at 60,000/well for use in high-throughput screening protocols as described previously (Green et al., 2000, 2001).
Mitochondrial membrane potential was measured in intact cells using an assay based on a fluorescence quenching assay between two dyes: NAO (Molecular Probes) that stains cardiolipin, a lipid found exclusively in the mitochondrial inner membrane; and TMR (Molecular Probes), a potentiometric dye taken up by mitochondria in accordance with Nernstian dictates of potential and concentration. The presence of TMR quenches NAO emission in proportion to m, whereas loss of m with consequent efflux of TMR reduces the quenching of NAO fluorescence. The high specificity of NAO staining; selective monitoring of the fluorescence emitted by NAO, not TMR; and the stringent requirement for colocalization of both dyes within the mitochondrion all act in concert to allow the fluorescence quenching assay to report m unconfounded by background signal arising from potentiometric dye responding to plasma membrane potential. Lipid Peroxidation Measurement. Lipid peroxidation was monitored by measuring malondiadehyde (MDA), a stable end product of lipid peroxidation cascades using the thiobarbituric acid reactive substances (TBARS) assay. As one of the main compounds among TBARS, MDA reacts with TBA under acid conditions and high heat, and the product of this reaction can be detected spectrometrically or fluorometrically. SK-N-SH cells were plated in 60-mm dishes at the density of 2.0 x 106 cells/dish 48 h before experiments. After 2-h preincubation of estrogens or vehicle, cells were exposed to 150 µM H2O2 for 5 min with the presence of estrogens or vehicle. Cells were washed twice with ice-cold PBS and harvested with 0.6 ml/dish ice-cold PBS using rubber policeman. Then, cells were homogenized by sonication. To prevent sample oxidation during homogenization, 0.5 M BHT (10 µl/ml cell suspension) was added before sonication. Cell homogenates were centrifuged at 3000g at 4°C for 10 min. The clear supernatant was used for TBARS assay and protein determination. For MDA measurement, 100 µl of sample was added into 48-well plate followed by addition of a solution containing 1% TBA, 12.5% trichloroacetic acid, and 0.8 N HCl. Reaction mixtures were incubated at 50°C for 60 min, and then precipitated proteins were removed by centrifuging at 12,000 rpm for 2 min. Supernatants were transferred to 96-well plates, and relative fluorescence values were determined using a BioTek FL600 plate reader (BioTek, Highland Park, VT) at an excitation wavelength of 530 ± 25 nm, emission wavelength of 590 ± 20 nm, and sensitivity of 100. External standards used in the TBARS assay were made from 1,1,3,3-tetramethoxypropane in reagent grade ethanol and diluted in 0.9% normal saline to give concentrations ranging from 0 to 20 µM.
Measurement of Cytosolic ROS. The extent of cytosolic cellular oxidative stress was estimated by monitoring the amount of ROS by the fluorescent dye DCFH-DA. Cells were plated 24 h before initiation of the experiment at a density of 15,000 cells/well in 96-well plates. Cells were loaded with DCFH-DA at a final concentration of 50 µM for 45 min. After incubation, DCFH-DA was removed, and cells were washed twice with PBS, pH 7.4, and incubated with minimum Eagle's medium containing 20% fetal bovine serum with a bolus dose of 50 or 100 µM H2O2 for 10 to 60 min. DCF2,7-dichlorofluorescin fluorescence was determined at an excitation of 485 nm and an emission of 538 nm using an FL600 microplate-reader (BioTek, Highland Park, VT). Values were normalized to percentage of untreated control groups.
Reduced Glutathione Measurement. Cellular GSH levels were determined using Northwest Life Science Specialties Glutathione Assay kit (Northwest Life Science Specialties, LLC, Vancouver, WA). Cells were seeded in 100-mm dishes at the density of 5.0 x 106 cells/dish. Forty-eight hours later, cells were exposed to various treatments. After treatments, cells were washed with PBS twice, and samples were collected as manufacturer's direction. GSH levels were normalized to the protein concentrations.
Protein Assays. Protein concentration was determined by the method of Bradford (Bradford, 1976) using bovine serum albumin at concentrations ranging from 0 to 1 mg/ml as a standard curve.
Data Analysis. All data are presented as mean ± S.E.M. Comparisons between estrogen-treated groups and vehicle (H2O2 + vehicle) groups were performed using one-way ANOVA with Tukey's multiple comparisons test. For all tests, p < 0.05 was considered significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-E2 dose dependently increased cell survival. At the concentration of 100 nM, 17-E2 increased cell survival from 49 ± 2 to 64 ± 3%. One µM 17-E2 increased cell viability from 45 ± 7 to 74 ± 5%.
|
-E2 and ent-E2, also showed protective effects against H2O2 toxicity. At the concentration of 1 µM, 17-E2 and ent-E2 enhanced cell viability from 57 ± 1% to 72 ± 2 and 91 ± 2%, respectively (Fig. 2B). ICI 182,780 alone (300 nM) significantly protected from H2O2 toxicity and did not block the protection from 100 nM 17-E2 (Fig. 2C).
Effects of Estrogens on H2O2-Induced [Ca +]i Increase. After 30-min incubation, 150 µM H2O2 increased [Ca2+]i to 460 ± 35 nM, whereas [Ca2+]i in vehicle only treated groups was approximately 80 ± 7 nM. Two-hour pretreatment with 17-E2 dose dependently reduced the increase in [Ca2+]i induced by H2O2. One hundred nanomolar 17-E2 reduced [Ca2+]i levels to 247 ± 11 nM, and 1 µM 17-E2 lowered [Ca2+]i levels to 162 ± 9 nM (Fig. 3A).
|
With 2-h pretreatment, both 17-E2 and ent-E2 significantly inhibited H2O2-induced [Ca2+]i increase (Fig. 3B). At 1 µM concentration, 17-E2 and ent-E2 reduced the H2O2 effects on [Ca2+]i by 64 and 56%, respectively. The protective effects of 17-E2 on H2O2-induced [Ca2+]i increase were consistently not blocked by coadministration of 300 nM ICI 182,780. On the other hand, ICI 182,780 alone caused a 57% decrease in [Ca2+]i in cells exposed to H2O2 (Fig. 3C).
Effects of Estrogens on H2O2-Induced Mitochondrial Calcium Loading. Administration of 150 µM H2O2 increased mitochondrial calcium level to 147 ± 6% of baseline (Fig. 4), which was completely blocked by 2-h pretreatment of 1 µM 17-E2. Furthermore, 17-E2 and ent-E2 at 1 µM had similar effect on mitochondrial calcium protection against H2O2 insult (Fig. 4).
|
). After 8 to 12 h, ATP levels were approximately 40% of control (data not shown).
As shown in Fig. 5A, 17-E2 protected SK-N-SH cells against H2O2-induced ATP depletion. Two-hour pretreatment with 17-E2 dose dependently reversed the decline of intracellular ATP induced by 100 µM H2O2. The ATP levels were completely restored to normal by 1 µM 17-E2 (from 58 ± 5 to 98 ± 12% of control). Similar effects were also demonstrated in 17-E2 and ent-E2 (Fig. 5, B and C). At the concentration of 100 nM and 1 µM, 17-E2 restored intracellular ATP levels from 56 ± 6% to 68 ± 2 and 89 ± 7% of control, respectively. One micromolar ent-E2 inhibited H2O2-induced ATP declines from 37 ± 4 to 59 ± 5%.
|
m collapse in SK-N-SH cells. As might be expected, the concentration of H2O2 required to cause acute collapse of m was substantially more than the concentration required for long-term cytotoxicity studies. 17-E2 significantly reduced the magnitude of m collapse induced by H2O2 (Fig. 6A). Treatments with 17-E2 and ent-E2 at 1 µM reduced the magnitude of m collapse but not as effectively as 17-E2 (Fig. 6B).
|
-, 17-, and ent-E2 all significantly and dose dependently attenuated lipid peroxidation. Among three compounds, 17-E2 showed highest efficacy. At 1 µM, 17-, 17-, and ent-E2 reduced MDA levels to from 2.51 ± 1.1 nmol/mg of protein to 1.51 ± 0.10, 1.27 ± 0.05, and 1.39 ± 0.16 nmol/mg of protein, respectively.
|
Effects of Estrogens against H2O2-Induced GSH Depletion. To further investigate estrogens antioxidant properties, we examined their effects on intracellular antioxidant-GSH levels. Six-hour treatment of H2O2 reduced intracellular total GSH levels from 18.5 ± 0.4 to 10.7 ± 0.7 nmol/mg of protein in SK-N-SH cells. Three estrogens, 17-, 17-, and ent-E2 all significantly alleviated GSH depletion at concentrations ranging from 1 nM to 1 µM. At 1 µM, estrogens enhanced GSH concentrations to 87% or higher of normal levels (Fig. 8). Concentrations of 17-E2 ranging from 1 nM to 10 µM failed to reduce cytosolic ROS, as determined by DCFH-DA fluorescence (data not shown).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-, 17-, and ent-E2 protected against H2O2-incuded toxicity. The protective effects of the these three estrogens includes a potent attenuation of lipid peroxidation, enhanced cell survival, attenuated ATP depletion, alleviated intracellular calcium elevation, and ablated mitochondrial calcium loading and subsequent mitochondrial membrane potential maintenance. Furthermore, the ER antagonist ICI 182,780 did not block effects of 17-E2 but increased cell survival and blunted intracellular calcium increase induced by H2O2. These data suggest that the protective effects of estrogens in SK-N-SH cells are independent of ER-mediated genomic effects and are likely to involve a potent protection from lipid peroxidation.
ROS are implicated in neuronal damage and neurodegenerative diseases such as stroke and Alzheimer's disease (Brunelle and Rauk, 2002). Exposure to H2O2 induces a robust increase in ROS in cells; followed by oxidation of lipids, proteins, and DNA; increase in intracellular calcium; glutathione depletion; mitochondria dysfunction; caspase-3 activation; and subsequent necrotic and apoptotic cell death. ROS have been shown to allow the influx of calcium, and this effect of oxidation is implicated in many neurodegenerative diseases (Gibson et al., 2002; Mattson, 2003; Zheng et al., 2003) Likewise, rapid disruption in cellular calcium leads to apoptosis (Simpkins et al., 2005). In our study, exposure to 150 µM H2O2 induces a rapid 4- to 5-fold elevation of the cellular free calcium levels within 30 min. After 18 h treatment, approximately 50% of cells died, which was accompanied by a dramatic increase in caspase-3 activation (data not shown). These findings agree with other studies showing that an early increases in intracellular calcium results in apoptosis (Yu et al., 2001). All three estrogens ablated H2O2-induced [Ca2+]i increases. Furthermore, ER antagonist ICI 182,780 not only did not affect the protection by 17-E2 but also significantly attenuated H2O2 -induced [Ca2+]i increase. This agonist activity of ICI 182,780 has also been observed by other laboratories (O'Neill and Brinton, 2004).
The mechanisms involved in attenuation of [Ca2+]i elevation by estrogen is not known. 17-E2 may exert this protective effect through both preventing extracellular calcium influx and inhibiting calcium release from intracellular calcium stores. Studies suggest that estradiol affects the Na+-Ca2+ exchanger (Cross et al., 1998; Sugishita et al., 2001). Estrogen has been shown to modulate L-type Ca2+ channels in neuronal cells (Kim et al., 2000). In glial cells, estrogen has been demonstrated to inhibit both N-methyl-D-aspartate and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, thereby, reducing Ca2+ influx (Lopez et al., 1997). The attenuation of [Ca2+]i elevation in the early phase of H2O2 insult may contribute to the overall protective effects of estrogens.
Mitochondria are a major intracellular calcium store and mitochondrial calcium concentrations are critical in maintaining mitochondrial membrane potential and oxidative phosphorylation. Mitochondrial calcium overloading leads to mitochondrial membrane potential collapse and initiates cell death. Exposure of 150 µM H2O2 for 30 min induced a 50% increase in mitochondrial calcium levels. All three estrogens blunted H2O2-induced mitochondrial calcium influx. Studies from our laboratory and others also have shown that 17-E2 attenuates mitochondrial calcium overloading against oxidative stress (Wang et al., 2001b; Nilsen and Diaz Brinton, 2003). Mitochondrial calcium loading depends on uptake through the uniporter and efflux by Na+-Ca2+ exchanger on mitochondrial membrane (Crompton et al., 1978). It has been shown that 17-E2 increases Na+-dependent calcium efflux exponentially at concentrations above 10 nM in synaptosomal mitochondria (Horvat et al., 2000). The ability of estrogens to maintain mitochondrial calcium levels may be closely related to their modulatory effect on intracellular calcium homeostasis and mitochondrial sequestration of calcium under oxidative stress.
In the present study, we demonstrate that three estrogens restored cellular ATP levels against H2O2 toxicity. These results are consistent with previous studies on the effect of estrogen on ATP levels against various stressors. 17-E2 has shown to protect against ATP depletion, mitochondrial membrane potential decline, and the generation of reactive oxygen species induced by mitochondrial toxin 3-nitropropionic acid (Wang et al., 2001a). 17-, 17-, and ent-E2 can protect human lens epithelial cells against H2O2-induced ATP depletion and mitochondrial potential collapse (Wang et al., 2003). E2 stabilizes mitochondrial function against actions of mutant presenilin-1 (Mattson et al., 1997) and inhibits mitochondrial F0F1-ATP synthase/ATPase by binding to one of its subunits (Zheng and Ramirez, 1999). Estrogen can attenuate oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid -peptide and iron (Keller et al., 1997). In cerebral blood vessels, E2 enhanced expression of mitochondrial specific proteins such as cytochrome c and subunit IV of complex IV (Stirone et al., 2005). Besides mitochondrial stabilization, estrogens may blunt ATP loss by enhancing ATP production from glycolysis. Estradiol has been reported to increase glyceraldehydes-3-phosphate dehydrogenase activity in the central nervous system (Ramirez et al., 2001). Furthermore, ER has been found located in the mitochondria of variety of tissues (Monje and Boland, 2001; Yang et al., 2004). The mitochondrial localization of ER suggests that ER could play a role in the effects of estrogens on mitochondria function.
Mitochondrial calcium sequestration and ATP production are closely correlated with mitochondrial membrane potential. 17-, 17-, and ent-E2 effectively protected mitochondria from H2O2-induced membrane potential collapse. These data are consistent with other studies that show that 17-E2 treatment stabilizes mitochondrial potential against oxidative stress such as 3-nitropropionic acid (Wang et al., 2001a) and mutant presenilin-1 (Mattson et al., 1997). Mounting evidence suggests that estrogens, acting as mitochondrial energizers by targeting mitochondrial sites to inhibit opening of permeability transition pores, inhibit the mitochondrial calcium uniport, increase mitochondrial-specific proteins expression, cause recovery of ATP production, and up-regulate the antiapoptotic protein Bcl-2 (Nilsen and Diaz Brinton, 2003; Burris and Krishnan, 2005; Stirone et al., 2005).
To investigate the mechanisms underlying the antioxidant effects of estrogen, we evaluated the ability of 17-, 17-, and ent-estradiol to scavenge ROS and to prevent lipid peroxidation. We demonstrated that 150 µM H2O2 exposure significantly increased MDA levels within 5 min in SK-N-SH cells. In addition, all three estrogens effectively inhibited H2O2-induced lipid peroxidation at concentrations ranging from 1 nM to 1 µM. The quick action and high potency of estrogens indicate their effect on attenuating lipid peroxidation may serve as the primary role in neuroprotection. In contrast, 17-E2 did not reduce H2O2 exposure-induced cytosolic ROS increase with concentrations ranging from 1 nM to 10 µM (data not shown). Based on these observations, we propose that cellular membranes are one of the primary targets of antioxidant effects of estrogen. The antioxidant actions of estrogen on cell membranes are ER-independent, and the phenolic A-ring structure may play an important role in this effect. Mounting evidence shows that estradiol inhibits lipid peroxidation (Behl et al., 1995; Goodman et al., 1996; Gridley et al., 1997). Sugioka et al. (1987) first postulated that the phenolic A-ring is closely related with the effect of estrogen on inhibiting lipid peroxidation. Studies from Jellnick and Bradlow (1990) have shown that estrogens can inhibit oxidative cascades by donating hydrogen radicals on the A-ring of estrogens.
To further address the antioxidant properties of estrogen, we examined estrogens action on cellular GSH levels. Glutathione is an important cellular antioxidant and exerts its antioxidant activity through several mechanisms, including scavenging free radicals (Meister and Anderson, 1983). Previous studies from our laboratory showed the synergistic interaction between estrogens and glutathione in protecting neuronal cells against oxidative stress (Green et al., 1998; Gridley et al., 1998). In the presence of 3.25 µM GSH, the ED50 value of 17-E2 decreased from 3.27 µM to 5 nM against -amyloid toxicity in HT-22 cells. In our current study, all three estrogens significantly increased intracellular GSH levels with dosages ranging from 1 nM to 1 µM. This evidence suggests the involvement of GSH in neuroprotection by estrogen.
We compared the potency of estrogens against various cytotoxic responses to H2O2 in SK-N-SH cells in an attempt to determine the primary mechanism of neuroprotection. In most cases, the effective concentrations of these estrogens were from 100 nM to 1 µM, consistent with effective antioxidant dosages from other studies. However, at the concentration of 1 nM, these estrogens significantly inhibit lipid peroxidation after 5-min H2O2 exposure. Based upon this time and potency relationship, we propose that inhibition of lipid peroxidation is the primary mechanism of estrogen protection in SK-N-SH cells followed by attenuation of intracellular calcium elevations, stabilization of mitochondrial Ca2+ and 
m, preservation of ATP and GSH levels, and subsequent inhibition of cell death.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: E2, estrogen; ROS, reactive oxygen species; ER, estrogen receptor; AM, acetoxymethyl ester; ICI 182,780, fulvestrant; DCFH-DA, 2,7-dichlorofluorescin diacetate; NAO, nonyl acridine orange; TMR, tetramethylrhodamine; rhod, rhodamine; TBA, 2-thiobarbituric acid; PBS, phosphate-buffered saline; HBSS, HEPES-buffered salt solution; m, mitochondrial membrane potential; MDA, malondialdehyde; TBARS, thiobarbituric acid reactive substances; GSH, reduced glutathione; ANOVA, analysis of variance.
Address correspondence to: Dr. James W. Simpkins, Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107. E-mail: jsimpkin{at}hsc.unt.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Bae YH, Hwang JY, Kim YH, and Koh JY (2000) Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci 15: 327-336.[Medline]
Bagger YZ, Tanko LB, Alexandersen P, Qin G, and Christiansen C (2005) Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 12: 12-17.[CrossRef][Medline]
Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, and Holsboer F (1997) Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51: 535-541.
Behl C, Widmann M, Trapp T, and Holsboer F (1995) 17-beta Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 216: 473-482.[CrossRef][Medline]
Birge SJ (1996) Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 44: 865-870.[Medline]
Bishop J and Simpkins JW (1994) Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Mol Cell Neurosci 5: 303-308.[CrossRef][Medline]
Blum-Degen D, Haas M, Pohli S, Harth R, Romer W, Oettel M, Riederer P, and Gotz ME (1998) Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death. Toxicol Appl Pharmacol 152: 49-55.[CrossRef][Medline]
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.[CrossRef][Medline]
Brunelle P and Rauk (2002) The radical model of Alzheimer's disease: specific recognition of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: an ONIOM study. J Alzheimers Dis 4: 283-289.[Medline]
Burris TP and Krishnan V (2005) Estrogen: a mitochrondrial energizer that keeps on going. Mol Pharmacol 68: 956-958.
Chen J, Xu W, and Jiang H (2001) 17 beta-estradiol protects neurons from ischemic damage and attenuates accumulation of extracellular excitatory amino acids. Anesth Analg 92: 1520-1523.
Costa MM, Reus VI, Wolkowitz OM, Manfredi F, and Lieberman M (1999) Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 46: 182-188.[CrossRef][Medline]
Crompton M, Moser R, Ludi H, and Carafoli E (1978) The interrelations between the transport of sodium and calcium in mitochondria of various mammalian tissues. Eur J Biochem 82: 25-31.[Medline]
Cross HR, Lu L, Steenbergen C, Philipson KD, and Murphy E (1998) Overexpression of the cardiac Na+/Ca2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female, transgenic mice. Circ Res 83: 1215-1223.
Culmsee C, Vedder H, Ravati A, Junker V, Otto D, Ahlemeyer B, Krieg JC, and Krieglstein J (1999) Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab 19: 1263-1269.[CrossRef][Medline]
De Girolamo L, Hargreaves AJ, and Billett EE (2001) Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J Neurochem 76: 650-660.[CrossRef][Medline]
Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, and Wise PM (1998) Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 18: 1253-1258.[CrossRef][Medline]
Fukuda K, Yao H, Ibayashi S, Nakahara T, Uchimura H, Fujishima M, and Hall ED (2000) Ovariectomy exacerbates and estrogen replacement attenuates photothrombotic focal ischemic brain injury in rats. Stroke 31: 155-160.
Garewal HS, Ahmann FR, Schifman RB, and Celniker A (1986) ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst 77: 1039-1045.[Medline]
Gibson GE, Zhang H, Xu H, Park LC, and Jeitner TM (2002) Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme. Biochim Biophys Acta 1586: 177-189.[Medline]
Goodman Y, Bruce AJ, Cheng B, and Mattson MP (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid betapeptide toxicity in hippocampal neurons. J Neurochem 66: 1836-1844.[Medline]
Green PS, Bishop J, and Simpkins JW (1997a) 17 alpha-estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 17: 511-515.
Green PS, Gordon K, and Simpkins JW (1997b) Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol 63: 229-235.[CrossRef][Medline]
Green PS, Gridley KE, and Simpkins JW (1996) Estradiol protects against betaamyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218: 165-168.[CrossRef][Medline]
Green PS, Gridley KE, and Simpkins JW (1998) Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience 84: 7-10.[CrossRef][Medline]
Green PS, Perez EJ, Calloway T, and Simpkins JW (2000) Estradiol attenuation of beta-amyloid-induced toxicity: a comparison o. J Neurocytol 29: 419-423.[CrossRef][Medline]
Green PS and Simpkins JW (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18: 347-358.[CrossRef][Medline]
Green PS, Yang SH, Nilsson KR, Kumar AS, Covey DF, and Simpkins JW (2001) The nonfeminizing enantiomer of 17beta-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology 142: 400-406.
Gridley KE, Green PS, and Simpkins JW (1997) Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 778: 158-165.[CrossRef][Medline]
Gridley KE, Green PS, and Simpkins JW (1998) A novel, synergistic interaction between 17-estradiol and glutathione in the protection of neurons against -amyloid 25-35-induced toxicity in vitro. Mol Pharmacol 54: 874-8780.
Gunter TE and Pfeiffer DR (1990) Mechanisms by which mitochondria transport calcium. Am J Physiol 258: C755-C786.[Medline]
Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, and Buckwalter JG (1994) Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51: 896-900.
Horvat A, Petrovic S, Nedeljkovic N, Martinovic JV, and Nikezic G (2000) Estradiol affect Na-dependent Ca2+ efflux from synaptosomal mitochondria. Gen Physiol Biophys 19: 59-71.[Medline]
Jellinck PH and Bradlow HL (1990) Peroxidase-catalyzed displacement of tritium from regiospecifically labeled estradiol and 2-hydroxyestradiol. J Steroid Biochem 35: 705-710.[CrossRef][Medline]
Keller JN, Germeyer A, Begley JG, and Mattson MP (1997) 17-Estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport and glutamate transport induced by amyloid beta-peptide and iron. J Neurosci Res 50: 522-530.[CrossRef][Medline]
Kim YJ, Hur EM, Park TJ, and Kim KT (2000) Nongenomic inhibition of catecholamine secretion by 17beta-estradiol in PC12 cells. J Neurochem 74: 2490-2496.[CrossRef][Medline]
Liu R, Yang SH, Perez E, Yi KD, Wu SS, Eberst K, Prokai L, Prokai-Tatrai K, Cai ZY, Covey DF, et al. (2002) Neuroprotective effects of a novel non-receptor-binding estrogen analogue: in vitro and in vivo analysis. Stroke 33: 2485-2491.
Lopez T, Lopez-Colome AM, and Ortega A (1997) NMDA receptors in cultured radial glia. FEBS Lett 405: 245-248.[CrossRef][Medline]
Mattson MP (2003) Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 3: 65-94.[CrossRef]
Mattson MP, Robinson N, and Guo Q (1997) Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. Neuroreport 8: 3817-3821.[Medline]
Meister A and Anderson ME (1983) Glutathione. Annu Rev Biochem 52: 711-760.[CrossRef][Medline]
Melov S (2000) Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging. Ann NY Acad Sci 908: 219-225.[Medline]
Mendelowitsch A, Ritz MF, Ros J, Langemann H, and Gratzl O (2001) 17-Estradiol reduces cortical lesion size in the glutamate excitotoxicity model by enhancing extracellular lactate: a new neuroprotective pathway. Brain Res 901: 230-236.[CrossRef][Medline]
Monje P and Boland R (2001) Subcellular distribution of native estrogen receptor alpha and beta isoforms in rabbit uterus and ovary. J Cell Biochem 82: 467-479.[CrossRef][Medline]
Moosmann B and Behl C (1999) The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 96: 8867-8872.
Nilsen J and Diaz Brinton R (2003) Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci USA 100: 2842-2847.
O'Neill KJ and Brinton RD (2004) Neural estrogenic effects of ICI 182,780. Soc Neurosci Abstr 30: 659.11.
Perez E, Liu R, Yang SH, Cai ZY, Covey DF, and Simpkins JW (2005) Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res 1038: 216-222.[CrossRef][Medline]
Pike CJ (1999) Estrogen modulates neuronal Bcl-xL expression and beta-amyloidinduced apoptosis: relevance to Alzheimer's disease. J Neurochem 72: 1552-1563.[CrossRef][Medline]
Ramirez VD, Kipp JL, and Joe I (2001) Estradiol, in the CNS, targets several physiologically relevant membrane-associated proteins. Brain Res Brain Res Rev 37: 141-152.[CrossRef][Medline]
Regan RF and Guo Y (1997) Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia and excitatory amino acids in murine cortical cultures. Brain Res 764: 133-140.[CrossRef][Medline]
Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, and Shimohama S (1998) Estradiol protects mesencephalic dopaminergic neurons from oxidative stressinduced neuronal death. J Neurosci Res 54: 707-719.[CrossRef][Medline]
Sherwin BB (1996) Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynecol 87: 20S-26S.[CrossRef][Medline]
Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, Yu CJ, Bodor N, and Day AL (1997) Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 87: 724-730.[Medline]
Simpkins JW, Wang J, Wang X, Perez E, Prokai L, and Dykens JA (2005) Mitochondria play a central role in estrogen-induced neuroprotection. Curr Drug Targets CNS Neurol Disord 4: 69-83.[CrossRef][Medline]
Singer CA, Figueroa-Masot XA, Batchelor RH, and Dorsa DM (1999) The mitogenactivated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19: 2455-2463.
Singer CA, Rogers KL, and Dorsa DM (1998) Modulation of Bcl-2 expression: a potential component of estrogen protection in NT2 neurons. Neuroreport 9: 2565-2568.[Medline]
Singer CA, Rogers KL, Strickland TM, and Dorsa DM (1996) Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 212: 13-16.[CrossRef][Medline]
Stirone C, Duckles SP, Krause DN, and Procaccio V (2005) Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 68: 959-965.
Sudo S, Wen TC, Desaki J, Matsuda S, Tanaka J, Arai T, Maeda N, and Sakanaka M (1997) beta-Estradiol protects hippocampal CA1 neurons against transient forebrain ischemia in gerbil. Neurosci Res 29: 345-354.[CrossRef][Medline]
Sugioka K, Shimosegawa Y, and Nakano M (1987) Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 210: 37-39.[CrossRef][Medline]
Sugishita K, Su Z, Li F, Philipson KD, and Barry WH (2001) Gender influences [Ca2+] (i) during metabolic inhibition in myocytes overexpressing the Na+-Ca2+ exchanger. Circulation 104: 2101-2106.
Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, and Mayeux R (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432.[CrossRef][Medline]
Wang J, Green PS, and Simpkins JW (2001a) Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem 77: 804-811.[CrossRef][Medline]
Wang J, Yi KD, Narayan S, Zhang X, Wang X, and Simpkins JW (2001b) Effects of 17-estradiol on 3-nitroproprionic acid-induced increases in cytosolic calcium in SK-N-SH neuroblastoma cells and HT-22 murine hippocampal cells (Abstract 873.18). Soc Neurosci Abstr 27: 2323.
Wang X, Simpkins JW, Dykens JA, and Cammarata PR (2003) Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP and cell viability. Investig Ophthalmol Vis Sci 44: 2067-2075.
Wilson ME, Dubal DB, and Wise PM (2000) Estradiol protects against injuryinduced cell death in cortical explant cultures: a role for estrogen receptors. Brain Res 873: 235-242.[CrossRef][Medline]
Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M, and Rosewell KL (2001) Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Brain Res Rev 37: 313-319.[CrossRef][Medline]
Yaffe K, Sawaya G, Lieberburg I, and Grady D (1998) Estrogen therapy in post-menopausal women: effects on cognitive function and dementia. J Am Med Assoc 279: 688-695.
Yang SH, Liu R, Perez EJ, Wen Y, Stevens SM Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, Will Y, Dykens J, et al. (2004) Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci USA 101: 4130-4135.
Yu SP, Canzoniero LM, and Choi DW (2001) Ion homeostasis and apoptosis. Curr Opin Cell Biol 13: 405-411.[CrossRef][Medline]
Zaulyanov LL, Green PS, and Simpkins JW (1999) Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol 19: 705-718.[CrossRef][Medline]
Zheng J and Ramirez VD (1999) Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na+,K+-ATPase of porcine cortex. Eur J Pharmacol 368: 95-102.[CrossRef][Medline]
Zheng Z, Lee JE, and Yenari MA (2003) Stroke: molecular mechanisms and potential targets for treatment. Curr Mol Med 3: 361-372.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  E.-S. Y. Lee, Z. Yin, D. Milatovic, H. Jiang, and M. Aschner Estrogen and Tamoxifen Protect against Mn-Induced Toxicity in Rat Cortical Primary Cultures of Neurons and Astrocytes Toxicol. Sci., July 1, 2009; 110(1): 156 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Jung, A. M. Wilson, X. Ju, Y. Wen, D. B. Metzger, and J. W. Simpkins Ethanol Withdrawal Provokes Opening of the Mitochondrial Membrane Permeability Transition Pore in an Estrogen-Preventable Manner J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 692 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Flynn, D. A. Lannigan, D. E. Clark, M. H. Garner, and P. R. Cammarata RNA suppression of ERK2 leads to collapse of mitochondrial membrane potential with acute oxidative stress in human lens epithelial cells Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E589 - E599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Straub The Complex Role of Estrogens in Inflammation Endocr. Rev., August 1, 2007; 28(5): 521 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhao, K. O'Neill, and R. D. Brinton Estrogenic Agonist Activity of ICI 182,780 (Faslodex) in Hippocampal Neurons: Implications for Basic Science Understanding of Estrogen Signaling and Development of Estrogen Modulators with a Dual Therapeutic Profile J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1124 - 1132. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
